| Four Small Caps for Binary Event Investors Mike Havrilla submits:Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA news/decisions or clinical trial results that are expected within the next three months. A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events approximately 3-6 months ahead of the expected catalyst date, and sell into the expected upward momentum in both stock price and trading volume. Click here for a four-minute video that includes an overview of mikehavRx.com and this binary event investing strategy. Extreme trades such as those profiled below can be viewed as call option trades due to their low stock prices and high risk/reward profile. For this reason, investing in a basket of several low-priced stocks with pending binary events and following the strategy outlined above is an effective way to mitigate the risk of investment losses while participating in the potential run-up in stock price as the catalyst date approaches. Complete Story » seekingalpha.com |
Why Titan Pharma's on My Radar This Week VFC submits: Titan Pharmaceuticals (TTNP.OB) is a company and a 'Stock to Watch' this week after shares closed over ten percent to the upside on Monday, most likely in anticipation of a decision by the United States Patent and Trademark Office that is expected to be rendered on Tuesday, June 15th regarding Titan's Probuphine patent.Any extended patent life for Probuphine would significantly boost the value and future potential of Titan Pharmaceuticals, a company already reaping the 8-10% royalty rewards from the Fanapt licensing agreement. Titan has also been awarded a grant from the National Institutes of Health to cover up to $8 million of the cost of the Probuphine confirmatory Phase III trial.Complete Story » seekingalpha.com |
Chairman and Chief Scientist at ERT Recognized as One of 100 Most Inspiring People in the Life Sciences Industry (PR Newswire) ERT , a leading provider of centralized services to global pharmaceutical, biotechnology and medical device companies, announces that Joel Morganroth, MD, Chairman and Chief Scientist, has been acknowledged by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry. Â Dr. us.rd.yahoo.com |
Alyson Stoner Tips for Crest & Oral-B - Video First and only complete line of oral care products for kids eight and up help encourage healthy oral care habits feedproxy.google.com |
GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500 [PR Newswire] - GeneLink BioSciences, Inc. , a leading consumer genomics biotech company, today announced that it ranked number 62 on Technology Fast 500â„¢, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Â Rankings are based on percentage of fiscal year growth during the period from 2005-2009. Â GeneLink grew 2057 percent during this period. us.rd.yahoo.com |